touchONCOLOGY

Apr 29, 2024 | touchoncology.com | Toshinari Yamashita

Breast Cancer Read Time: 12 mins Copy Link Published Online: Apr 29th 2024 touchREVIEWS in Oncology & Haematology. 2024;20(1):1–4:Online ahead of journal publication Authors: Toshinari Yamashita Quick Links: Overview Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based on the results of the DESTINY-Breast 01, 02 and 03 studies.

Apr 25, 2024 | touchoncology.com | Chelsea Stewart |Dana Chase

The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1 Platinum-based chemotherapy had long been the standard of care in patients with advanced or recurrent endometrial cancer. New approaches to the classification of endometrial cancer based on the molecular profile have allowed for a more targeted approach to treatment.

Mar 7, 2024 | touchoncology.com | Florence Pasquier |Stephane de Botton

Leukaemia Read Time: 14 mins Copy Link Published Online: Mar 7th 2024 touchREVIEWS in Oncology & Haematology. 2024;20(1):1–5:Online ahead of journal publication Authors: Florence Pasquier, Stéphane De Botton Quick Links: Overview Management of patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) is challenging, as their prognosis remains poor with conventional therapies, underlining the need for the development of new drugs.

Oct 3, 2023 | touchoncology.com | Jeremy D. Kratz |Nataliya V. Uboha

Gastrointestinal Cancers Read Time: 15 mins Copy Link Published Online: Oct 3rd 2023 touchREVIEWS in Oncology & Haematology. 2023;19(2):22-28 DOI: https://doi.org/10.17925/OHR.2023.19.2.1 Authors: Jeremy D Kratz, Nataliya V Uboha Quick Links: Overview Immune checkpoint inhibitors allow innate immune cells to recognize and attack tumour cells by removing inhibitory signals associated with tumours and their microenvironment.

Apr 24, 2023 | touchoncology.com | Linda Martin

Lung Cancer Read Time: 3 mins Published Online: April 24th 2023 touchREVIEWS in Oncology & Haematology. 2023;19(1):Online ahead of journal publication Authors: Linda Martin Abstract: Overview Linda Martin is Associate Professor at the University of Virginia, Chief of Thoracic Surgery and leads the Thoracic Oncology Tumor Board, in addition to co-leading the Enhanced Recovery Program for Thoracic Surgery.